Treatment of inflammatory dermatoses by tumour necrosis factor antagonists

Journal of the European Academy of Dermatology and Venereology

Volumn 20, Issue 10, 2006, Pages 1171-1187

  Jacobi, Arnd ^a   Mahler, V ^a   Schuler, G ^a   Hertl, M ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Adalimumab; Etanercept; Inflammatory skin disorders; Infliximab; Psoriasis vulgaris et arthropatica; TNF inhibitors

Indexed keywords

ADALIMUMAB; ADRENALIN; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; AZATHIOPRINE; CIPROFLOXACIN; CORTICOSTEROID; CORTISONE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DITHRANOL; ETANERCEPT; ETRETIN; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INFLIXIMAB; ISONIAZID; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOXIFYLLINE; PREDNISONE; PSORALEN; RETINOID; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG;

ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BEHCET DISEASE; BULLOUS SKIN DISEASE; CHEST TIGHTNESS; CHRONIC INFLAMMATION; CLINICAL TRIAL; CYTOPENIA; DEMYELINATING DISEASE; DISEASE EXACERBATION; DIZZINESS; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SPECIFICITY; DRUG STRUCTURE; DYSPNEA; FLUSHING; GRAFT VERSUS HOST REACTION; GRANULOMA ANNULARE; HEART FAILURE; HUMAN; HYPERTENSION; INJECTION SITE REACTION; LEUKOPENIA; LICHEN; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MYALGIA; NAUSEA; PITYRIASIS RUBRA PILARIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; PUVA; PYODERMA GANGRENOSUM; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; SARCOIDOSIS; SCLERODERMA; SECOND CANCER; SKIN INFLAMMATION; SKIN MANIFESTATION; SKIN TOXICITY; SOLID TUMOR; STAPHYLOCOCCUS INFECTION; SUBCORNEAL PUSTULAR DERMATOSIS; SYSTEMIC VASCULITIS; TOXIC EPIDERMAL NECROLYSIS; TUBERCULOSIS; WEGENER GRANULOMATOSIS;

DERMATOLOGIC AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SKIN DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33750300029     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01733.x     Document Type: Review

References (80)

1. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatol Treat 2004; 15: 280-294.
2. LaDuca JR, Gaspari AA. Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases. Dermatol Clin 2001; 19: 617-635.
3. Voigtlaender C, Lueftl M, Schuler G, Hertl M. Infliximab (anti-tumor necrosis factor-α antibody) - A novel, highly effective treatment for recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson Disease). Arch Dermatol 2001; 137: 1571-1574.
4. Lebwohl MG. Use of etanercept in the dermatology setting: A review. Am J Clin Dermatol 2005; 6: 49-59.
5. Geyer AS, Anhalt GJ, Nousari HC. Effectiveness of infliximab in the treatment of refractory perineal cutaneous Crohn's disease. Arch Dermatol 2000; 136: 459-460.
6. Maini R, St. Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor-α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. Lancet 1999; 354: 1932-1939.
7. Thoma-Uszynski S, Eming R. Novel therapeutic approaches in autoimmune skin disorders. In: Hertl M, ed. Autoimmune Diseases of the Skin: Pathogenesis, Diagnosis, Management. Springer Verlag, Vienna, 2005: 421-456.
8. Gottlieb AB. Infliximab for psoriasis. J Am Acad Dermatol 2003; 49: 112-117.
9. Ogilvie ALJ, Antoni C, Dechant C et al. Treatment of psoriatic arthritis with antitumour necrosis factor-α antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001; 144: 587-589.
10. Mease PJ. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 2002; 61: 298-304.
11. Patel T, Gordon KB. Adalimumab: Efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther 2004; 17: 427-431.
12. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis: A randomized controlled trial. Ann Intern Med 1999; 130: 478-486.
13. Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088-1094.
14. Scheinberg MA. Treatment of recurrent oral aphthous ulcers with etanercept. Clin Exp Rheumatol 2002; 20: 733-734.
15. Basu A, Wexner SD Perianal Crohn's disease. Curr Treat Options Gastroenterol 2002; 5: 197-206.
16. Mahadevan U, Sandborn WJ. Infliximab for the treatment of orofacial Crohn's disease. Inflamm Bowel Dis 2001; 7: 38-42.
17. Papadakis K, Shaye OA, Vasiliauskas EA et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005; 100: 75-79.
18. Sandborn WJ, Hanauer S, Loftus EV et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004; 99: 1984-1989.
19. Jenne L, Sauter B, Thumann P, Hertl M, Schuler G. Successful treatment of therapy-resistant chronic vegetating pyoderma gangrenosum with infliximab (chimeric anti-tumor necrosis factor-α antibody). Br J Dermatol 2004; 150: 380-382.
20. Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000; 284: 1546-1548.
21. Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn's disease with anti-tumor necrosis factor-α monoclonal antibody. Arch Dermatol 2001; 137: 930-933.
22. Hubbard VG, Friedmann AC, Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol 2005; 152: 1059-1061.
23. McGowan JW, Johnson CA, Lynn A. Treatment of pyoderma gangrenosum with etanercept. J Drugs Dermatol 2004; 3: 441-444.
24. Chaudari U, Romano P, Mulcahy LD et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet 2001; 357: 1842-1847.
25. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000; 42: 829-830.
26. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 2002; 46: 886-891.
27. O'Quinn RP, Miller JL. The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: A report of 2 cases. Arch Dermatol 2002; 138: 644-648.
28. Reich K, Nestle F, Ortonne JP et al. Infliximab produces a sustained and significant improvement in psoriasis over 50 weeks of continuous therapy. Br J Dermatol 2005; 153 (Suppl 1): Abstract no: 10.
29. Gordon KB, Leonardi C, Menter MA, Langley R, Chen DM. Adalimumab efficacy and safety in patients with moderate to severe chronic plaque psoriasis: Preliminary findings from a 12-week dose-ranging trial. Poster at the Annual Meeting of the American Academy of Dermatology, Washington DC, 2004.
30. Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: Observations on combination therapy. Br J Dermatol 2002; 146: 118-121.
31. Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-1312.
32. Wollina U, Konrad H. Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-alpha antibody. J Eur Acad Dermatol Venereol 2002; 16: 127-129.
33. Antoni C, Dechant C, Lorenz HM et al. Open-label study of infliximab treatment for psoriatic arthritis: Clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002; 47: 506-512.
34. Antoni C, Manger B. Infliximab for psoriasis and psoriatic arthritis. Clin Exp Rheumatol 2002; 20: 122-125.
35. Antoni CE, Kavanaugh A, Kirkham B et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52: 1227-1236.
36. Chew AL, Bennett A, Smith CH, Barker J, Kirkham B. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br J Dermatol 2004; 151: 492-496.
37. Genovese MC, Mease PJ, Thomson GTD et al. Adalimumab Efficacy in patients with psoriatic arthritis who failed prior DMARD therapy. Poster at the EULAR, Vienna, 10 June 2005.
38. Mease PJ, Goffe BS, Metz J et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 2000; 356: 385-390.
39. Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264-2272.
40. Proksch E, Ulrich C, Wiedow O, Schreiber S, Christophers E. Treatment with anti-tumor necrosis factor antibody dramatically improves generalized pustular psoriasis. Arch Dermatol Res 2001; 293: 101.
41. Kazinski K, Joyce KM, Hodson D. The successful use of etanercept in combination therapy for treatment of acrodermatitis continua of Hallopeau. J Drugs Dermatol 2005; 4: 360-364.
42. Goossens PH, Verburg RJ, Breedveld FC. Remission of Behçet's syndrome with tumour necrosis factor-α-blocking therapy. Ann Rheum Dis 2001; 60: 637.
43. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: A case report. Gastroenterology 2001; 120: 995-999.
44. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 2001; 49: 725-728.
45. Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab. Rheumatology 2001; 40: 473-474.
46. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 2001; 358: 295-296.
47. Estrach C, Mpofu S, Moots RJ. Efficacy and safety of infliximab and adalimumab in Behçet's syndrome. 67th Annual Scientific Meeting of the American College of Rheumatology, Orlando, Florida, 2003.
48. Melikoglu M, Fresko I, Mat C et al. Etanercept is beneficial in controlling the mucocutaneous lesions of Behçet's syndrome (BS) at short term but does not suppress the pathergy reaction and the cutaneous response to intradermally injected monosodium urate (MSU) crystals: A double blind, placebo controlled trial. Ann Rheum Dis 2002; 61 (Suppl. 1): 37.
49. Melikoglu M, Ozyazgan Y, Fresko I et al. The response of treatment resistant uveitis in Behçet's Syndrome (BS) to a TNF-alpha blocker, etanercept: An open study. Arthritis Rheum 2002; 46 (Suppl. 9): 181.
50. Estrach C, Mpofu S, Moots RJ. Behçet's syndrome: Response to infliximab after failure of etanercept. Rheumatology 2002; 41: 1213-1214.
51. Hertl MS, Haendle I, Schuler G, Hertl M. Rapid improvement of recalcitrant disseminated granuloma annulare upon treatment with the tumour necrosis factor-alpha inhibitor, infliximab. Br J Dermatol 2005; 152: 552-555.
52. Fayyazi A, Schweyer S, Eichmeyer B et al. Expression of IFN-γ, coexpression of TNF-α and matrix metalloproteinases and apoptosis of T lymphocytes and macrophages in granuloma annulare. Arch Dermatol Res 2000; 292: 384-390.
53. Feliciani C, Toto P, Amerio P et al. In vitro and in vivo expression of interleukin-1α and tumor necrosis factor-α mRNA in pemphigus vulgaris: Interleukin-1α and tumor necrosis factor-α are involved in acantholysis. J Invest Dermatol 2000; 114: 71-77.
54. Lopez-Robles E, Avalos-Diaz E, Vega-Memije E et al. TNFα and IL-6 are mediators in the blistering process of pemphigus. Int J Dermatol 2001; 40: 185-188.
55. Jacobi A, Schuler G, Hertl M. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumor necrosis factor-alpha inhibitor infliximab. Br J Dermatol 2005; 153: 448-449.
56. Sacher C, Rubbert A, Konig C et al. Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J Am Acad Dermatol 2002; 46: 113-115.
57. Liao WC, Mutasim DF. Infliximab for the treatment of adult-onset pityriasis rubra pilaris. Arch Dermatol 2005; 141: 423-425.
58. Jacobi A, Antoni C, Manger B, Schuler G, Hertl M. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005; 3: 522-526.
59. Marenco JL, Gonzalez P, Montero SR et al. Treatment with infliximab in systemic scleroderma. EULAR Annual Congress of Rheumatology, 2002.
60. Ellmann MH, McDonald PA, Hayes FA. Etanercept as treatment for diffuse scleroderma: A pilot study. Arthritis Rheum 2000; 43: 392.
61. Gruschwitz MS, Albrecht M, Vieth G, Haustein UF. In situ expression and serum levels of tumor necrosis factor-alpha receptors in patients with early stages of systemic sclerosis. J Rheumatol 1997; 24: 1936-1943.
62. Charles PJ, Smeenk RJT, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α. Arthritis Rheum 2000; 43: 2383-2390.
63. Gershon S, Wise RP, Niu M, Siegel JN. Postlicensure reports of infection during use of etanercept and infliximab. ACR 64th Annual Scientific Meeting, Philadelphia, 2000.
64. 1-Fc fusion complex therapy. J Am Acad Dermatol 2001; 45: 953-956.
65. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Siegel JN. Demyelination diagnosed during etanercept (TNF receptor fusion protein) therapy. ACR 64th Annual Scientific Meeting, Philadelphia, 2000.
66. Torre-Amione G, Vooletich MT, Farmer JA. Role of tumour necrosis factor-alpha in the progression of heart failure: Therapeutic implications. Drugs 2000; 59: 745-751.
67. Fischer M, Fiedler E, Marsch WC, Wohlrab J. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002; 146: 707-709.
68. Jonasdottir O, Bendtzen K, Skjodt H, Petersen J. Elevated serum levels of soluble tumor-necrosis-factor receptors in Wegener's granulomatosis. Arthritis Rheum 1998; 41 (Suppl.): 116.
69. Lamprecht P, Voswinkel J, Lilienthal T et al. Effectiveness of TNF-α blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology 2002; 41: 1303-1307.
70. Booth AD, Jefferson HJ, Ayliffe W, Andrews PA, Jayne DR. Safety and efficacy of TNF-α blockade in relapsing vasculitis. Ann Rheum Dis 2002; 61: 559.
71. Stone JH, Uhlfelder ML, Hellmann DB et al. Etanercept combined with conventional treatment in Wegener's granulomatosis: A six-month open-label trial to evaluate safety. Arthritis Rheum 2001; 44: 1149-1154.
72. Langford CA, Talar-Williams C, Barron KS, McCabe KE, Sneller MC. Phase I/ II trial of etanercept in Wegener's granulomatosis (WG): Safety and preliminary experience. Arthritis Rheum 2000; 43 (Suppl.): 163.
73. Stone JH et al. Etanercept plus standard therapy for Wegener's granulomatosis. N Eng J Med 2005; 352: 351-361.
74. Kobbe G, Schneider P, Rohr U et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse anti-TNF-alpha antibody. Bone Marrow Transplant 2001; 28: 47-49.
75. Chiang KY, Abhyankar S, Bridges K, Godder K, Henslee-Downey PJ. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 2002; 73: 665-667.
76. Oyama Y, Ali Y, Tallman M et al. TNF-α blockade with etanercept for successful therapy of refractory acute and chronic graft-versus-host disease. Blood 2001; 98: 360b.
77. Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med 2001; 135: 27-31.
78. Matzkies FG, Manger B, Schmitt-Haendle M et al. Severe septicaemia in a patient with polychondritis and Sweet's syndrome after initiation of treatment with infliximab. Ann Rheum Dis 2003; 62: 81-82.
79. Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005; 64 (Suppl. 2): 49-54.
80. Sterry W, Barker J, Boehncke WH et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004; 151 (Suppl. 69): 3-17.